Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14026668 | 0.91 | PARP1 (0.84) | PARP1 | |
| SCHEMBL1251400 | 0.88 | PARP1 (0.78) | PARP1 | |
| SCHEMBL1249701 | 0.86 | PARP1 (0.76) | PARP1 | |
| SCHEMBL4438543 | 0.84 | PARP1 (1.00) | PARP1 | |
| SCHEMBL1252285 | 0.84 | PARP1 (0.71) | PARP1 | |
| SCHEMBL1249593 | 0.84 | PARP1 (0.71) | PARP1 | |
| SCHEMBL4447148 | 0.84 | PARP1 (1.00) | PARP1 | |
| SCHEMBL1251489 | 0.84 | PARP1 (0.71) | PARP1 | |
| SCHEMBL1251330 | 0.82 | PARP1 (0.68) | PARP1 | |
| SCHEMBL1249810 | 0.82 | PARP1 (0.68) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9283222-B2 | Inhibitors of poly(ADP-ribose)polymerase | ABBVIE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2698062-B1 | Inhibitors of poly(adp-ribose)polymerase | ABBVIE INC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140212509-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2698062-A1 | Inhibitors of poly(adp-ribose)polymerase | Abbvie Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2120579-B1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8466150-B2 | Inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2013-06-18 | — | — | US | disclosed |
| EP-2281818-A1 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-09 | — | — | EP | disclosed |
| EP-2120579-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| WO-2008083027-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-20050085476-A1 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1477175-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | PARP1, DPYD, PARP2 | PARP1 1/4885 |
| US-20050085476-A1 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | MUSK, RNASE1, DPYD | PARP1 4/4885 |
| US-20140212509-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | PARP1 1/4885 |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | MUSK, RNASE1, DPYD | PARP1 4/4885 |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | PARP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.